Over the past two decades, myopia has evolved from a regional concern to a worldwide medical phenomenon.
According to a recent study, over 2.6 billion people are now affected globally, with projections estimating that half the world's population will be myopic by 2050.
This alarming trend is not simply a matter of inconvenience—it carries significant implications for ocular health systems, refractive error management, and vision-threatening complications.
Clinically, myopia is characterized by an axial elongation of the eyeball, where the eye grows too long relative to its focusing power. This results in light rays converging in front of the retina, rather than directly on it, leading to blurry distance vision. Recent genetic studies have identified over 200 gene variants associated with myopia, yet environmental and behavioral factors are now recognized as primary drivers of this epidemic.
A core contributor to rising myopia rates is the increased visual demand placed on the near focus system due to prolonged screen use. Extended periods of accommodation—the eye's ability to maintain focus on close objects can lead to accommodative lag, disrupting the normal emmetropization process during childhood and adolescence.
A study highlights that children engaging in over four hours of screen time daily exhibited significantly greater axial elongation than peers with less than one hour. Devices such as smartphones and tablets not only increase accommodative stress but also reduce the frequency of blink rate and gaze shifting, both of which are critical for ocular health maintenance.
Another compelling theory is the lack of outdoor exposure to natural light, particularly during childhood. Several studies show that ultraviolet exposure stimulates dopamine release in the retina, which in turn slows axial elongation.
Dr. Christine F. Wildsoet highlights, "Children need a minimum of two hours of outdoor daylight exposure daily to significantly reduce their risk of developing myopia."
Mild myopia may be correctable, but its progression into high myopia poses a substantial medical threat. Axial elongation beyond 26mm increases the risk of posterior segment complications, including myopic maculopathy, vitreous degeneration, and retinal detachment.
These conditions are not only difficult to treat but can result in irreversible vision impairment. In addition, a 2024 study found that high myopia significantly raises the likelihood of developing glaucomatous optic nerve damage, even in patients without elevated intraocular pressure.
Medical management of progressive myopia has shifted from passive correction to active intervention. Among the most clinically supported options are:
- Low-dose atropine (0.01%) eye drops, which have demonstrated efficacy in reducing axial elongation with minimal side effects.
- Orthokeratology (Ortho-K) lenses, which temporarily reshape the cornea overnight, are shown to slow axial length increase when properly supervised by ophthalmologists.
- Multifocal soft contact lenses, are gaining popularity in pediatric populations due to improved safety profiles and comfort.
The rapid global increase in myopia prevalence demands not only preventive strategies but also continuous clinical surveillance. Pediatricians, ophthalmologists, and optometrists are encouraged to screen children as early as age 3, especially those with a family history of myopia. Moreover, integrating behavioral counseling on screen time and outdoor exposure into routine care may become a cornerstone of pediatric vision management.
Myopia should no longer be dismissed as a mere inconvenience. It is a progressive condition with serious long-term medical consequences when left unmanaged. Understanding its multi-factorial origins from environmental triggers to underlying neurochemical pathways enables more targeted and evidence-based interventions. With continued research and interdisciplinary collaboration, the trajectory of this global vision crisis can be altered.